Loading quotes...
Forecast
The analysts' average price target is €12.03 (+2.82%). The median is €12.27 (+4.87%).
| Buy |
2 |
| Hold |
8 |
| Sell |
1 |
News Go to news feed
Enhabit to be acquired for $1.10 billion at $13.80, creating near-term floor
Kinderhook Industries agreed to buy Enhabit for $13.80 per share in an approximately $1.10 billion deal expected to close in Q2 2026, giving the stock a defined acquisition floor. Enhabit has surged 48.16% year-to-date and 60.14% over the past year, while hospice revenue grew 10% in Q4 2025 and full-year operating cash flow rose 38.1% to $70.7 million. Home health admissions increased 7.3%, cost per patient day fell 3.5%, and leverage improved to 3.9x, underpinning operational and balance-sheet improvement ahead of the close. » More on finance.yahoo.com
Enhabit to be acquired by Kinderhook for about $1.1 billion
Kinderhook Industries is acquiring Enhabit in a transaction valued at about $1.1 billion. Shareholders will receive $13.80 per share in cash, representing a premium of roughly 24% to Friday's closing price. The deal is expected to close in the second quarter of 2026 and triggered a premarket rise in Enhabit’s stock of about 22.5%. » More on de.investing.com
Enhabit expects better quarter: consensus EPS at $0.142
Analyst consensus expects Enhabit to report earnings of $0.142 per share for the quarter ended December 31, 2025, versus -$0.920 in the year-ago quarter. Revenue is expected on average to be $270.6 million (prior year $258.2 million). For the fiscal year analysts forecast a mean EPS of $0.563 and revenue of about $1.06 billion versus $1.03 billion in the prior year. » More on finanzen.net
Financials
| (EUR) | March 2026 | YoY |
|---|---|---|
| Revenue | 228.76m | - |
| Gross profit | 108.85m | - |
| Net profit | 16.59m | - |
| EBITDA | 32.48m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €628.79m |
Number of shares | 51.23m |
52-week high/low | €12.65 - €5.76 |
| Dividends | No |
Beta | 0.96 |
P/E ratio | -230.00 |
PEG ratio | -0.69 |
P/B ratio | 1.28 |
P/S ratio | 0.66 |
Company profile
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.
| Name | Enhabit, Inc. |
| CEO | Barbara Ann Jacobsmeyer |
| Headquarters | Dallas,
tx USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 23/06/2022 |
| Employees | 10,600 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | EHAB |
Frankfurt | X34.F |
Düsseldorf | X34.DU |